ºñ¹ÙÀÌ·¯½º À¯ÀüÀÚ Àü´Þ ±â¼ú ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¸ðµåº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Non-viral Gene Delivery Technologies Market Size, Share & Trends Analysis Report By Mode (Chemical, Physical), By Application (Research, Therapeutics), By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1654345
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,194,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,571,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,325,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºñ¹ÙÀÌ·¯½º À¯ÀüÀÚ Àü´Þ ±â¼ú ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é Àü ¼¼°è ºñ¹ÙÀÌ·¯½º À¯ÀüÀÚ Àü´Þ ±â¼ú ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 71¾ï 1õ¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç ¿¹Ãø ±â°£ µ¿¾È 2025³âºÎÅÍ 2030³â±îÁö 12.29%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯ÀüÀÚ Ä¡·á ¹× ¿¬±¸¿¡¼­ ¹ÙÀÌ·¯½º º¤ÅÍ¿¡ ´ëÇÑ ¾ÈÀüÇϰí È®Àå °¡´ÉÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ ´ë¾È¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀåÀÇ ¼ºÀåÀÌ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ·¯½º ¹æ½Ä°ú ´Þ¸® ÁöÁú ³ª³ëÀÔÀÚ(LNP), Æú¸®¸Ó, Àü±â õ°ø°ú °°Àº ºñ¹ÙÀÌ·¯½º ±â¼úÀº ¸é¿ª¿ø¼ºÀÌ ³·°í Á¦Á¶ º¹À⼺ÀÌ °¨¼ÒÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Æ¯¼ºÀ¸·Î ÀÎÇØ mRNA ±â¹Ý ¹é½Å°ú CRISPR/Cas9 ±â¹Ý À¯ÀüÀÚ ÆíÁý Ä¡·á¹ýÀ» Æ÷ÇÔÇÑ ´ë±Ô¸ð ¾ÖÇø®ÄÉÀ̼ǿ¡ ¸Å¿ì ÀûÇÕÇÕ´Ï´Ù. ¸ð´õ³ª¿Í È­ÀÌÀÚ-¹ÙÀÌ¿À¿£ÅØÀÇ mRNA Äڷγª19 ¹é½ÅÀÇ ¼º°øÀº ºñ¹ÙÀÌ·¯½º Àü´Þ ½Ã½ºÅÛÀÇ ÀáÀç·ÂÀ» ´õ¿í ÀÔÁõÇÏ¿© ÀÌ ºÐ¾ß¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ÅõÀÚ¸¦ ÃËÁøÇß½À´Ï´Ù.

³ª³ë±â¼ú°ú »ýü Àç·áÀÇ ¹ßÀüÀº ÀÌ ºÐ¾ßÀÇ Çõ½ÅÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ³ª³ëÀÔÀÚ, ¸®Æ÷Ç÷º½º, ÇÏÀ̺긮µå ij¸®¾î´Â Çâ»óµÈ °¨¿° È¿À²°ú Ç¥Àû Àü´ÞÀ» À§ÇØ ÃÖÀûÈ­µÇ°í ÀÖ½À´Ï´Ù. ¾Ï, Èñ±Í À¯Àü Áúȯ, ½ÉÇ÷°ü ÁúȯÀ» ºñ·ÔÇÑ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀ̰í Á¤¹ÐÇÑ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ´ë·®ÀÇ À¯ÀüÀÚ ÆäÀ̷ε带 Àü´ÞÇÏ°í ¹Ýº¹ Åõ¿©¸¦ Áö¿øÇÏ´Â ºñ¹ÙÀÌ·¯½º ±â¼úÀº ÀÌ·¯ÇÑ ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¸¦ ÇØ°áÇÏ´Â µ¥ ÁßÃßÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ü¿Ü ¿¬±¸ ÀÀ¿ë ºÐ¾ß¿Í »ýü ³» Ä¡·á »ç¿ë »ç·Ê ¸ðµÎ¿¡¼­ ´Ù¿ëµµ·Î »ç¿ëÇÒ ¼ö ÀÖ¾î »ý¸í°øÇÐ, Á¦¾à ȸ»ç ¹× Çмú ±â°ü Àü¹Ý¿¡¼­ äÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ Ä¡·á ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ Àڱݰú ¹Î°£ ÅõÀÚ°¡ Áõ°¡ÇÏ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä µ¿ÀÎÀÔ´Ï´Ù. ºÏ¹Ì¿Í À¯·´°ú °°Àº Áö¿ªÀº R&D Ãø¸é¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖÁö¸¸, Áß±¹°ú Àεµ¿Í °°Àº ¾Æ½Ã¾Æ ÅÂÆò¾ç Áö¿ªÀÇ ½ÅÈï °æÁ¦±¹µéÀº ¹ÙÀÌ¿ÀÅ×Å© ÀÎÇÁ¶ó¿Í Áö¿ø ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÇ Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ý¸í°øÇÐ ±â¾÷°ú Çмú ±â°ü °£ÀÇ ÆÄÆ®³Ê½ÊÀº Çõ½ÅÀ» ÃËÁøÇÏ°í ºñ¹ÙÀÌ·¯½º Àü´Þ ¼Ö·ç¼ÇÀÇ Á¢±Ù¼ºÀ» È®´ëÇÏ¿© ºü¸£°Ô ÁøÈ­ÇÏ´Â À¯ÀüÀÚ Ä¡·á ºÐ¾ß¿¡¼­ÀÇ °ü·Ã¼ºÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

ºñ¹ÙÀÌ·¯½º À¯ÀüÀÚ Àü´Þ ±â¼ú ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¸ðµå ºñÁî´Ï½º ºÐ¼®

Á¦5Àå ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦6Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦7Àå ¸ðµå, ¿ëµµ, ÃÖÁ¾ ¿ëµµ¿¡ ÀÇÇÑ Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦8Àå °æÀï ±¸µµ

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Non-viral Gene Delivery Technologies Market Growth & Trends:

The global non-viral gene delivery technologies market size is anticipated to reach USD 7.11 billion by 2030 and grow at a CAGR of 12.29% from 2025 to 2030 during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is driven by the growing demand for safe, scalable, and cost-effective alternatives to viral vectors in gene therapy and research. Unlike viral methods, non-viral technologies such as lipid nanoparticles (LNPs), polymers, and electroporation offer lower immunogenicity and reduced manufacturing complexities. These attributes make them highly suitable for large-scale applications, including mRNA-based vaccines and CRISPR/Cas9-based gene editing therapies. The success of mRNA COVID-19 vaccines by Moderna and Pfizer-BioNTech further validated the potential of non-viral delivery systems, spurring global investment in this sector.

Advancements in nanotechnology and biomaterials are further accelerating innovation in the field. Nanoparticles, lipoplexes, and hybrid carriers are being optimized for enhanced transfection efficiency and targeted delivery. With the rising prevalence of chronic diseases, including cancer, rare genetic disorders, and cardiovascular conditions, the need for effective and precise therapeutic solutions has surged. Non-viral technologies, with their ability to deliver large genetic payloads and support repeat administrations, are pivotal in addressing these unmet medical needs. In addition, their versatility in both in vitro research applications and in vivo therapeutic use cases expands their adoption across biotechnology, pharmaceutical companies, and academic institutes.

The rising government funding and private investments in gene therapy research are also key drivers of market growth. Regions like North America and Europe lead in terms of R&D, but emerging economies in Asia-Pacific, such as China and India, are rapidly advancing due to increasing biotech infrastructure and supportive regulatory frameworks. Furthermore, partnerships between biotech companies and academic institutions are fostering innovation and expanding the accessibility of non-viral delivery solutions, ensuring their relevance in the rapidly evolving field of gene therapy.

Non-viral Gene Delivery Technologies Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Mode Business Analysis

Chapter 5. Application Business Analysis

Chapter 6. End Use Business Analysis

Chapter 7. Regional Business Analysis by mode, application, end use

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â